Literature DB >> 22282247

Renal impairment in multiple myeloma: presenting features in different departments.

Ni Li1,2, Yongman Lv1, Hongbing Zeng1, Fan He1, Ying Yao1, Xiaofeng He3.   

Abstract

In order to analyze the cai]ses of delayed diagnosis and raise the level of early diagnosis of atypical multiple myeloma (MM), the differences of presenting features between the patients presented to nephrologists and those presented to hematologists were compared. MM patients in our hospital were studied retrospectively. Those who referred renal impairment were divided into two groups: group I presented to nephrologists prior to MM diagnosis (n=29) and group II presented to hematologists directly (n=62). The age, sex, initial symptoms, haematological and biochemical parameters, the phenotype of paraprotein, bone marrow biopsy and cytology were undertaken and analyzed. The results showed that the median time between the initial symptoms and diagnosis in the patients of group I was longer than that in group II (P<0.001); patients in group I had significantly lower incidence of bone pain (P<0.01) and worse renal function (P<0.05) on presentation. There were lower level of myeloma cells (P<0.05), lower incidence of hypergammaglobulinemia (P<0.05), lower positive rate of monoclonal immunoglobulin (M protein) (P<0.05) and M protein level (P<0.05) in the patients of group I than those in group II. The ratio of monoclonal to lambda monoclonal proteins in a population was 1:3.67 in patients of group I, whereas 1:0.90 in patients of group II (P<0.01). Moreover, patients with λ type had a higher degree of renal insufficiency than those with κ type (P<0.05). It was suggested that the median time between the initial symptoms and diagnosis in the patients presented to nephrologists was longer than that in those presented to hematologists; the patients presented to nephrologists had the lower incidence of bone pain, lower level of myeloma cells and M protein, which made early diagnosis more difficult; more patients presented to nephrologists had the majority of λ light chain type, moreover, patients with λ light chain type had a higher incidence of renal insufficiency.

Entities:  

Mesh:

Year:  2012        PMID: 22282247     DOI: 10.1007/s11596-012-0011-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  13 in total

Review 1.  Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1a) in human multiple myeloma.

Authors:  Hiroyuki Hata
Journal:  Leuk Lymphoma       Date:  2005-07

2.  Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells.

Authors:  Sule Sengul; Craig Zwizinski; Vecihi Batuman
Journal:  Am J Physiol Renal Physiol       Date:  2003-02-11

3.  Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.

Authors:  L M Knudsen; M Hjorth; E Hippe
Journal:  Eur J Haematol       Date:  2000-09       Impact factor: 2.997

Review 4.  Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma.

Authors:  A D Clark; A Shetty; R Soutar
Journal:  Blood Rev       Date:  1999-06       Impact factor: 8.250

5.  Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.

Authors:  V Eleutherakis-Papaiakovou; A Bamias; D Gika; A Simeonidis; A Pouli; A Anagnostopoulos; E Michali; T Economopoulos; K Zervas; M A Dimopoulos
Journal:  Leuk Lymphoma       Date:  2007-02

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years.

Authors:  Shang-Yi Huang; Ming Yao; Jih-Luh Tang; Wen-Chung Lee; Woei Tsay; Ann-Li Cheng; Chiu-Hwa Wang; Yao-Chang Chen; Ming-Ching Shen; Hwei-Fang Tien
Journal:  Cancer       Date:  2007-08-15       Impact factor: 6.860

8.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.

Authors:  J Bladé; P Fernández-Llama; F Bosch; J Montolíu; X M Lens; S Montoto; A Cases; A Darnell; C Rozman; E Montserrat
Journal:  Arch Intern Med       Date:  1998-09-28

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

10.  Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies.

Authors:  M Leboulleux; B Lelongt; B Mougenot; G Touchard; R Makdassi; A Rocca; L H Noel; P M Ronco; P Aucouturier
Journal:  Kidney Int       Date:  1995-07       Impact factor: 10.612

View more
  1 in total

1.  Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis.

Authors:  Constantinos Koshiaris; Jason Oke; Lucy Abel; Brian D Nicholson; Karthik Ramasamy; Ann Van den Bruel
Journal:  BMJ Open       Date:  2018-06-22       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.